ClinicalTrials.gg
Active, not recruitingNCT05987332Updated Feb 17, 2026

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

A Phase 2/3 interventional study of IDE196 and Crizotinib in Metastatic Uveal Melanoma, sponsored by IDEAYA Biosciences. Active, not recruiting at 68 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by IDEAYA Biosciences · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 190 studies in Uveal Melanoma with a site in United States — 25 open to participants now, 50 under way, 7 of them phase 3. Uveal Melanoma · United States.

Planned enrollment
4th of 162
420 · median 36
Started
2023
with 6 others
Phase 2/3
2 of 190
1 open now
Primary completion
2027-01
later than 15 of 49 live
Registered
167th of 190
by date
Lead sponsor
5 of 190
IDEAYA Biosciences

Among the 190 studies in Uveal Melanoma with a site in United States, this one is the 4th largest by planned enrollment of the 162 interventional ones that give a count, is one of 7 that started in 2023, is one of 2 in phase 2/3, reaches primary completion later than 15 of the 49 other live ones, and was the 167th registered.

Uveal Melanoma

281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.

Browse Uveal Melanoma studies →

Open to participants now

25 of the 190 studies in Uveal Melanoma with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Uveal Melanoma studies recruiting now, 35 (83%) set no upper age limit and 4 (10%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 190 studies in Uveal Melanoma with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).

Read the detailed description

This study is designed as a multi-stage Phase 2 study within a Phase 3 study to evaluate the safety, tolerability, pharmacokinetics, dose-exposure relationship, and anti-tumor activity of IDE196 in combination with crizotinib compared to the comparator arm of investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).

The Phase 2a dose optimization stage will evaluate two doses of IDE196 in combination with crizotinib compared to the comparator arm. Participants will be randomized to the three treatment arms. At the point of optimal IDE196 + crizotinib dose selection, the other dose arm will be dropped with discontinuation of enrollment to that arm. Participants receiving the IDE196 dose (in combination with crizotinib) that is not selected, will be offered the choice to remain on the same dose or change to the chosen optimal dose.

The optimal dose will be chosen to complete the Phase 2b portion. The Phase 2b part of the study will continue to enroll the chosen combination dose of IDE196 + crizotinib compared with the comparator arm. Participants will be randomized to the two treatment arms.

The Phase 3 part of the study will continue to enroll the chosen combination dose of IDE196 + crizotinib compared with the comparator arm. Participants will be randomized to the two treatment arms to evaluate the primary endpoint of overall survival (OS).

03

Conditions studied

  • Metastatic Uveal Melanoma

Keywords

  • IDE196
  • Darovasertib
  • Protein Kinase C
  • Metastatic Uveal Melanoma
  • Melanoma
  • Ocular Oncology
  • Ophthalmology
  • Crizotinib
  • Ocular melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological confirmed Uveal Melanoma
  • HLA-A*02:01 negative
  • No prior systemic therapy in the metastatic or advanced setting regional or liver-directed therapy. Ablations or surgical resection of oligometastatic disease, and or adjuvant therapy is allowed
  • per 1.1
  • Able to be safely administered and absorb study therapy
  • performance status 0 or 1
  • of ≥3 months
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with a PKC inhibitor (including prior treatment with IDE196), an inhibitor directly targeting MET, or an inhibitor directly targeting GNAQ/11
  • Concurrent malignant disease
  • AEs from prior anti-cancer therapy that have not resolved to Grade ≤1
  • Symptomatic or untreated central nervous system (CNS) , or that require
  • High risk of syncope or falls
  • Known AIDS related illness
  • Active adrenal insufficiency, active colitis, or active inflammatory bowel disease
  • History of interstitial lung disease, active pneumonitis, or history of pneumonitis requiring steroids
  • Active infection requiring systemic antibiotic therapy or active /C
  • Major surgery, radiotherapy, or use of hematopoietic colony-stimulating factors (CSF) within 2 weeks prior to start of study drug
  • Females who are pregnant or breastfeeding
  • History of severe reactions (eg, anaphylaxis) to other biologic drugs or monoclonal antibodies
  • for treatment with investigator's choice therapies as per applicable labelling
  • History of stroke within the last 6 months of the first dose of study drug
  • Impaired Cardiac function or cardiac diseases, including angina pectoris or acute myocardial infarction \<= 6 months prior to start of study treatment
  • Has any other condition that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the opinion of the investigator, would make the participant inappropriate for entry into the study, including institutionalization on the basis of an official or court order
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
420 participants (estimated)

Study arms

  • Experimental
    Phase 2a Dose Optimization of IDE196 + crizotinib

    Multiple doses of IDE196 will be tested in combination with fixed dose of crizotinib to identify the optimal combination dose.

    Drug: IDE196 · Drug: Crizotinib

  • Experimental
    Phase 2b / 3 Chosen Combination dose of IDE196 + crizotinib

    Chosen combination dose of IDE196 + crizotinib will be tested in additional participants.

    Drug: IDE196 · Drug: Crizotinib

  • Active comparator
    Phase 2a / 2b / 3 Comparator Arm

    Participants will receive investigator's choice of Pembrolizumab, Ipilimumab + Nivolumab, or Dacarbazine.

    Drug: Pembrolizumab · Drug: Ipilimumab · Drug: Nivolumab · Drug: Dacarbazine

Interventions

  • DrugIDE196

    Dosed orally, twice daily

    Also known as: Darovasertib

  • Dosed orally, twice daily

    Also known as: XALKORI

  • IV administration every 3 weeks

    Also known as: Keytruda

  • IV administration every 3 weeks for 4 Cycles

    Also known as: Yervoy

  • IV administration every 3 Weeks for 4 Cycles, thereafter every 4 Weeks maintenance

    Also known as: Opdivo

  • IV administration every 3 Weeks

    Also known as: DTIC-Dome

06

What researchers measure

Primary outcomes

  1. Phase 2a: To determine the optimal dose of IDE196 + Crizotinib combination for Phase 2B and Phase 3 by evaluating the following:

    dose exposure response (safety and efficacy) relationship, plasma concentration profiles and pharmacokinetic (PK) parameters, treatment-emergent Adverse Events (TEAEs), laboratory abnormalities, electrocardiogram (ECG), and vital sign changes and study treatment discontinuation due to AEs.

    Time frame: Approximately 5 months

  2. Phase 2 Progression-Free Survival (PFS)

    by blinded independent central review (BICR) of IDE196 + Crizotinib compared to investigator's choice of treatment per RECIST v1.1

    Time frame: Approximately 2 years

  3. Phase 3 Overall Survival (OS) of IDE196 + Crizotinib compared to investigator's choice of treatment.

    OS from randomization to date of death due to any cause

    Time frame: Approximately 4 years

Secondary outcomes

  1. Safety of IDE196 + Crizotinib: Incidence of Adverse Events

    Treatment emergent adverse events will be summarized by all AEs, including by Grade ≥3, all treatment related AEs, all AEs leading to study drug modifications or discontinuations, all SAEs as measured by CTCAE v5.0.

    Time frame: Approximately 2 years

  2. Phase 2a: Dose-exposure-response of IDE196 as measured by correlating the concentration of IDE196 in plasma with safety and efficacy.

    Dose exposure response of IDE196.

    Time frame: Approximately 5 months

  3. Phase 2a: Dose-exposure-response of Crizotinib measured by correlating the concentration of Crizotinib in plasma with safety and efficacy.

    Dose exposure response of Crizotinib

    Time frame: Approximately 5 months

  4. Phase 2b + 3: Progression-Free Survival (PFS) per Investigator Assessment of IDE196 + Crizotinib compared to investigator's choice of treatment .

    PFS per RECIST v1.1

    Time frame: Approximately 2 years

  5. Objective Response Rate (ORR) per BICR and Investigator assessment of IDE196 + Crizotinib compared to investigator's choice of treatment

    ORR per RECIST v1.1

    Time frame: Approximately 2 years

  6. Duration of Response (DOR) per BICR and Investigator assessment of IDE196 + Crizotinib compared to investigator's choice of treatment

    DOR per RECIST v1.1

    Time frame: Approximately 2 years

  7. Change from baseline over time and between treatment arms in Global health status and quality of life will be assessed using the EORTC QLQ-C30 questionnaire.

    The score range for the EORTC QLQ-C30 is from 0 to 100, with higher scores indicating better functioning and better global health status and health-related in EORTC QLQ-C30 scores

    Time frame: Approximately 2 years

  8. Change from baseline over time and between treatment arms in

    EuroQoL (EQ)-5D-5L scores

    Time frame: Approximately 2 years

  9. Best Objective Response (BOR) per BICR and Investigator Assessment of IDE196 + Crizotinib compared to Investigator's choice of treatment

    Best Objective Response (BOR) per RECIST v1.1

    Time frame: Approximately 2 years

  10. Disease Control Rate (DCR) per BICR and Investigator Assessment of IDE196 + Crizotinib compared to investigator's choice of treatment.

    Disease Control Rate (DCR) per RECIST v1.1

    Time frame: Approximately 2 years

  11. Time to response as assessed by Investigator and BICR

    Time to response per RECIST v1.1

    Time frame: Approximately 2 years

07

Study locations

68 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Jan 2027, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2023
First posted
Aug 14, 2023
StartActual
Oct 31, 2023
Primary completionEst.
Jan 15, 2027
CompletionEst.
Jan 15, 2028
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05987332
Lead sponsor
IDEAYA Biosciences
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
Oct 31, 2023
Primary completion
Jan 15, 2027 (estimated)
Completion
Jan 15, 2028 (estimated)
Last update
Feb 17, 2026

Study contacts

Hetal Patel, MD, MSHS, CHCQM
study director · IDEAYA Biosciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Darovasertib

Start the discussion